BNT162b2、BBIBP-CorV 和 Gam-COVID-Vac 疫苗的免疫原性以及自然感染 SARS-CoV-2 后的免疫反应-来自塞尔维亚诺维萨德的一项比较研究。
Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia.
机构信息
Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Institute of Public Health of Vojvodina, Novi Sad, Serbia.
出版信息
PLoS One. 2022 Feb 2;17(2):e0263468. doi: 10.1371/journal.pone.0263468. eCollection 2022.
BACKGROUND
Mass vaccination is the key element in controlling current COVID-19 pandemic. Studies comparing immunogenicity of different COVID-19 vaccines are largely lacking. We aimed at measuring anti-S antibody (Ab) levels in individuals fully vaccinated with BNT162b2, BBIBP-CorV and Gam-COVID-Vac, as well as in COVID-19 convalescents.
METHODS
In this cross-sectional study, serum was collected from 400 age- and sex-matched participants, 100 fully vaccinated with BNT162b2, 100 with BBIBP-CorV and 100 with Gam-COVID-Vac on the 28th day after the second vaccine dose, and 100 recovered from COVID-19 at least 28 days after symptom(s) resolution. Sera were analyzed using the LIAISON SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia, Italy). Wilcoxon rank-sum or Kruskal-Wallis tests was used for comparison of Ab levels.
RESULTS
Highest mean value (210.11, SD = 100.42) was measured in the BNT162b2 group, followed by Gam-COVID-Vac (171.11, SD = 120.69) and BBIBP-CorV (68.50, SD = 72.78) AU/mL (p<0.001). Significant differences in antibody levels were found between BNT162b2 and BBIBP-CorV (p<0.001), BNT162b2 and Gam-COVID-Vac (p = 0.001), as well as BBIBP-CorV and Gam-COVID-Vac groups (p<0.001). Percentage of seropositive was 81% in the convalescent group, 83% in BBIBP-CorV vaccinated and 100% in BNT162b2 and Gam-COVID-Vac. When comparing measured antibody levels in vaccinated to those in COVID-19 recovered, significantly higher antibody levels were found for vaccinated with BNT162b2 (p<0.001), and with Gam-COVID-Vac (p<0.001), while for BBIBP-CorV there was no statistically significant difference (p = 0.641).
CONCLUSIONS
All three investigated vaccines, BNT162b2, BBIBP-CorV and Gam-COVID-Vac, provide robust immune response 28 days after the second dose of vaccine, in the majority of participants. All individuals vaccinated with BNT162b2 and Gam-COVID-Vac seroconverted, while in vaccinated with BBIBP-CorV and COVID-19 recovered seroconversion rates were lower. Although less potent compared to other two vaccines, immune response after BBIBP-CorV was similar to response measured in convalescents. Challenge still remains to examine dynamics and durability of immunoprotection.
背景
大规模疫苗接种是控制当前 COVID-19 大流行的关键因素。目前缺乏比较不同 COVID-19 疫苗免疫原性的研究。我们旨在测量完全接种 BNT162b2、BBIBP-CorV 和 Gam-COVID-Vac 的个体以及 COVID-19 恢复期个体的抗-S 抗体 (Ab) 水平。
方法
在这项横断面研究中，从 400 名年龄和性别匹配的参与者中采集血清，100 名参与者在第二次疫苗接种后第 28 天完全接种 BNT162b2，100 名参与者完全接种 BBIBP-CorV，100 名参与者完全接种 Gam-COVID-Vac，100 名 COVID-19 恢复期个体在症状缓解后至少 28 天。使用 Liaison SARS-CoV-2 S1/S2 IgG 测定法 (DiaSorin, Saluggia, Italy) 分析血清。使用 Wilcoxon 秩和检验或 Kruskal-Wallis 检验比较 Ab 水平。
结果
在 BNT162b2 组中测量到最高的平均 (210.11，SD = 100.42) 值，其次是 Gam-COVID-Vac (171.11，SD = 120.69) 和 BBIBP-CorV (68.50，SD = 72.78) AU/mL (p<0.001)。在 BNT162b2 和 BBIBP-CorV 之间 (p<0.001)、BNT162b2 和 Gam-COVID-Vac 之间 (p = 0.001) 以及 BBIBP-CorV 和 Gam-COVID-Vac 组之间 (p<0.001)，Ab 水平存在显著差异。恢复期个体的血清阳性率为 81%，BBIBP-CorV 接种组为 83%，BNT162b2 和 Gam-COVID-Vac 接种组为 100%。当比较接种疫苗和 COVID-19 恢复期个体的测量 Ab 水平时，发现 BNT162b2 (p<0.001) 和 Gam-COVID-Vac (p<0.001) 的接种疫苗者的 Ab 水平显著更高，而 BBIBP-CorV 则没有统计学意义上的差异 (p = 0.641)。
结论
三种研究疫苗（BNT162b2、BBIBP-CorV 和 Gam-COVID-Vac）在第二次疫苗接种后 28 天均能在大多数参与者中提供强大的免疫反应。所有接种 BNT162b2 和 Gam-COVID-Vac 的个体均发生血清转化，而接种 BBIBP-CorV 和 COVID-19 恢复期个体的血清转化率较低。尽管与其他两种疫苗相比效力较低，但 BBIBP-CorV 后的免疫反应与恢复期个体测量的反应相似。仍需要研究免疫保护的动态和持久性。
Zotero 插件